FCGR3A and cancer: The use of IdeS has been shown to enhance the efficacy of anti-cancer mAbs in in vitro assays supplemented with serum antibody [163] which was attributed to a reduction in competition for FcγRIIIA occupancy, although iFcγRIIIA signalling may also be a contributing factor.